Neuralink—FDA cited Neuralink animal lab for 'objectionable conditions' and record-keeping failures
FDA inspectors found 'objectionable conditions or practices' at Neuralink's animal testing facilities during June 2023 inspections, including missing calibration records and quality assurance failures. Separately, the USDA confirmed a 2019 Animal Welfare Act violation involving unapproved BioGlue that caused animal suffering, but it was hidden from public records. DOT also fined Neuralink $2,480 for hazardous materials transport violations in 2023.
Scoring Impact
| Topic | Direction | Relevance | Contribution |
|---|---|---|---|
| Animal Welfare | -against | primary | -1.00 |
| Consumer Protection | -against | primary | -1.00 |
| Corporate Governance | -against | secondary | -0.50 |
| Research Integrity | -against | primary | -1.00 |
| Overall incident score = | -0.387 | ||
Score = avg(topic contributions) × significance (high ×1.5) × confidence (0.59)× agency (negligent ×0.5)
Evidence (1 signal)
FDA cited Neuralink for 'objectionable conditions' in animal testing lab
FDA inspectors found 'objectionable conditions or practices' at Neuralink's California animal testing facilities during June 2023 inspections, including missing calibration records and quality assurance failures. FDA disclosed this in a November 2024 letter to Congress.